Beta-blocker therapy added to ACE inhibitors significantly improved NYHA class by at least one class (OR 1.80; 95% CI 1.33-2.43; p<0.0001) in patients with chronic heart failure.
Meta-Analysis
Effect estimate: OR 1.80 (95% CI 1.33-2.43)
p-value: p=<0.0001
BACKGROUND: The results of randomised control trials (RCTs) evaluating the effect of beta-blockers on functional status in patients with chronic heart failure are conflicting. AIM: To perform a systematic review and meta-analysis of RCTs evaluating the effect of beta-blockers on New York Heart Association (NYHA) classification and exercise tolerance in chronic heart failure. METHODS AND RESULTS: We selected 28 RCTs evaluating beta-blocker versus placebo in addition to ACE inhibitor therapy. Combined results of 23 RCTs showed that beta-blockers improved NYHA class by at least one class with odds ratio (OR) 1.80 (1.33-2.43) p<0.0001. Meta-analysis of 10 RCTs showed a significant prolongation of exercise time by 44.19 (6.62-81.75) s p=0.021. Combining 8 RCTs evaluating the maximal peak oxygen uptake and 9 RCTs evaluating 6-min walk distance showed that beta-blockers had no significant effect compared with placebo, p=0.484, and p=0.730, respectively. Combined results of the 23 RCTs showed significant reducing effect on all cause mortality with OR=0.69 (0.59-0.82) p<0.0001. CONCLUSION: Chronic use of a beta-blocker in conjunction with ACE inhibitor therapy improves dyspnoea and prolongs exercise tolerance time, but has no significant effect on 6-min walk test or maximal oxygen uptake in patients with heart failure.
Abdulla et al. (Fri,) conducted a meta-analysis in Chronic heart failure. Beta-blockers vs. Placebo was evaluated on Improvement in NYHA class by at least one class (OR 1.80, 95% CI 1.33-2.43, p=<0.0001). Beta-blocker therapy added to ACE inhibitors significantly improved NYHA class by at least one class (OR 1.80; 95% CI 1.33-2.43; p<0.0001) in patients with chronic heart failure.